Unicycive Therapeutics, Inc. financial data

Symbol
UNCY on Nasdaq
Location
Los Altos, CA
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 12 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 205% % -0.58%
Debt-to-equity 93% %
Return On Equity -184% % -242%
Return On Assets -95% % -55%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 21,491,396 shares -79%
Common Stock, Shares, Outstanding 20,850,363 shares -79%
Entity Public Float $18,679,544 USD -4.2%
Common Stock, Value, Issued $21,000 USD -79%
Weighted Average Number of Shares Outstanding, Basic 18,065,389 shares 103%
Weighted Average Number of Shares Outstanding, Diluted 18,065,389 shares 103%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense $12,173,000 USD -36%
General and Administrative Expense $19,382,000 USD 90%
Operating Income (Loss) $31,555,000 USD -8.2%
Nonoperating Income (Expense) $1,858,000 USD -130%
Net Income (Loss) Attributable to Parent $33,413,000 USD -45%
Earnings Per Share, Basic -0.33 USD/shares 28%
Earnings Per Share, Diluted 1 USD/shares 28%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $42,695,000 USD
Assets, Current $50,287,000 USD 33%
Property, Plant and Equipment, Net $75,000 USD 23%
Operating Lease, Right-of-Use Asset $249,000 USD -68%
Assets $50,611,000 USD 31%
Accounts Payable, Current $957,000 USD 75%
Accrued Liabilities, Current $2,762,000 USD -7.7%
Liabilities, Current $13,131,000 USD 26%
Operating Lease, Liability, Noncurrent $117,000 USD -75%
Liabilities $13,131,000 USD 22%
Retained Earnings (Accumulated Deficit) $113,158,000 USD -42%
Stockholders' Equity Attributable to Parent $37,480,000 USD
Liabilities and Equity $50,611,000 USD 31%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $8,903,000 USD -38%
Net Cash Provided by (Used in) Financing Activities $2,546,000 USD -94%
Net Cash Provided by (Used in) Investing Activities $16,000 USD -167%
Common Stock, Shares Authorized 400,000,000 shares 0%
Common Stock, Shares, Issued 20,850,363 shares -79%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $42,695,000 USD 32%
Interest Paid, Excluding Capitalized Interest, Operating Activities $6,000 USD 20%
Deferred Tax Assets, Valuation Allowance $19,668,000 USD 76%
Deferred Tax Assets, Gross $19,837,000 USD 75%
Operating Lease, Liability $265,000 USD -67%
Depreciation $8,000 USD -11%
Payments to Acquire Property, Plant, and Equipment $16,000 USD 167%
Lessee, Operating Lease, Liability, to be Paid $272,000 USD -69%
Property, Plant and Equipment, Gross $138,000 USD 50%
Operating Lease, Liability, Current $265,000 USD -51%
Lessee, Operating Lease, Liability, to be Paid, Year Two $118,000 USD -72%
Lessee, Operating Lease, Liability, to be Paid, Year One $118,000 USD -81%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $7,000 USD -89%
Deferred Tax Assets, Operating Loss Carryforwards $11,022,000 USD 84%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10,000,000 shares
Unrecognized Tax Benefits $1,985,000 USD 93%
Operating Lease, Payments $100,000 USD 0%
Additional Paid in Capital $150,617,000 USD 40%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance $169,000 USD 5%
Share-based Payment Arrangement, Expense $2,445,000 USD 5.5%
Interest Expense $90,000 USD 67%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares